Millennium Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Millennium Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,500	Closed	-$2.58M	–	6393
2025 Q3	$2.58M	Buy	+25,500	New	+$2.37M	﹤0.01%	3814
2024 Q2	–	Sell	-10,000	Closed	-$433K	–	6450
2024 Q1	$433K	Buy	+10,000	New	+$438K	﹤0.01%	4907
2023 Q4	–	Sell	-30,200	Closed	-$692K	–	6473
2023 Q3	$692K	Buy	+30,200	New	+$676K	﹤0.01%	4447
2023 Q2	–	Sell	-80,000	Closed	-$1.43M	–	6613
2023 Q1	$1.43M	Buy	+80,000	New	+$2.01M	﹤0.01%	3754
2021 Q4	–	Sell	-40,000	Closed	-$522K	–	7310
2021 Q3	$522K	Buy	+40,000	New	+$611K	﹤0.01%	5309
2021 Q2	–	Sell	-10,000	Closed	-$213K	–	7032
2021 Q1	$213K	Buy	10,000 +3,000	+43%	+$87K	﹤0.01%	5461
2020 Q4	$208K	Buy	+7,000	New	+$178K	﹤0.01%	4781

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Millennium Management's RYTM Position: Q1 2026 in Review

Millennium Management increased its Rhythm Pharmaceuticals (RYTM) stake by 142% in Q1 2026, buying an estimated $25.8M and bringing the position to 451,825 shares worth $39.3M. The position accounts for 0.02% of the portfolio, ranked #1013.

Millennium Management first reported a position in RYTM in Q2 2018 and has held it in 23 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Millennium Management held 451,825 shares of Rhythm Pharmaceuticals worth $39.3M as of Q1 2026.
Millennium Management bought 265,116 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $25.8M.
Rhythm Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1013 holding.
Millennium Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 23 quarters since.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.